Literature DB >> 26740242

Formulation and process considerations for the design of sildenafil-loaded polymeric microparticles by vibrational spray-drying.

Moritz Beck-Broichsitter1,2, Adam Bohr3, Leticia Aragão-Santiago4, Andreas Klingl5, Thomas Kissel2.   

Abstract

CONTEXT AND
OBJECTIVE: The current study reports the preparation and characterization of sildenafil-loaded poly(lactide-co-glycolide) (PLGA)-based microparticles (MPs) by means of vibrational spray-drying. Emphasis was placed on relevant formulation and process parameters with influence on the properties of obtained powders. Materials and methods, results and discussion: The solid state solubility of sildenafil in spray-dried PLGA-MPs amounted to 17 wt.%. Thus, a drug loading below and above the determined solubility limit resulted in solid solutions and phase separation (i.e. solid dispersions), respectively. Furthermore, interactions between sildenafil and the PLGA matrix were observed for the spray-dried MPs. Optimization of spray-drying conditions allowed for a fabrication of defined MPs (size range of ∼4-8 μm) displaying a high sildenafil encapsulation efficiency (>90%) and sustained sildenafil release (from ∼4 to >12 h). The individual drug release rates from the spray-dried formulations were mainly a function of the drug loading, applied polymer and MP size. Finally, a scale-up of the preparation process did not result in a relevant change of the physicochemical and in vitro drug release properties of the prepared powders.
CONCLUSION: Identification of relevant formulation and spray-drying parameters enabled the fabrication of tailored sildenafil-loaded PLGA-based MPs, which meet the needs of the individual application (e.g. controlled drug delivery to the lungs).

Entities:  

Keywords:  Controlled drug delivery; lungs; poly(lactide-co-glycolide)

Mesh:

Substances:

Year:  2016        PMID: 26740242     DOI: 10.3109/10837450.2015.1098661

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  4 in total

1.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

Review 2.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

Review 3.  Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension.

Authors:  Victor Segura-Ibarra; Suhong Wu; Nida Hassan; Jose A Moran-Guerrero; Mauro Ferrari; Ashrith Guha; Harry Karmouty-Quintana; Elvin Blanco
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

4.  Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments.

Authors:  Mosab Arafat; Muhammad Sarfraz; Salahdein AbuRuz
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.